Search

Your search keyword '"Gonzales, Naomi R."' showing total 15 results
Start Over Author "Gonzales, Naomi R."
15 results on '"Gonzales, Naomi R."'

14. Combination therapy with topotecan, paclitaxel, and bevacizumab improves progression-free survival in patients with recurrent high-grade neuroendocrine cervical cancer: a Neuroendocrine Cervical Tumor Registry (NeCTuR) study

Author

Frumovitz, Michael, primary, Chisholm, Gary B., additional, Jhingran, Anuja, additional, Ramalingam, Preetha, additional, Flores-Legarreta, Alejandra, additional, Bhosale, Priya, additional, Gonzales, Naomi R., additional, Hillman, R. Tyler, additional, and Salvo, Gloria, additional

Published
2022
Full Text
View/download PDF

15. RB1 alteration and poor prognosis in women with high-grade neuroendocrine carcinoma of the uterine cervix: a NeCTuR study.

Author

Legarreta, Alejandra Flores, Salvo, Gloria, Gonzales, Naomi R., Chisholm, Gary, Hillman, R. Tyler, and Frumovitz, Michael

Subjects
NEUROENDOCRINE tumors, CERVIX uteri, OVERALL survival, MERKEL cell carcinoma, CERVIX uteri tumors
Abstract

Objective: To describe the gene alteration status in high-grade neuroendocrine cervical carcinoma (NECC) specimens and to explore the potential association of unique gene alterations with survival. Methods: Results from tumor-based molecular testing on specimens from women with high- grade NECC in the Neuroendocrine Cervical Tumor Registry were reviewed and analyzed. Tumor specimens could be from primary or metastatic sites and obtained at initial diagnosis, during treatment, or at recurrence. Results: Molecular testing results were available for 109 women with high-grade NECC. The genes most frequently mutated were PIK3CA (mutated in 18.5% of patients), TP53 (17.4%), and MYC (14.5%). Other targetable alterations identified were alterations in KIT (7.3%), KRAS (7.3%), and PTEN (7.3%). Women with tumors having an RB1 alteration (6.4%) had a median overall survival (OS) of 13 months, compared to 26 months for women with tumors that did not have an RB1 alteration (p=0.003). None of the other genes evaluated were shown to be associated with OS. Conclusion: Although no individual alteration was found in a majority of tumor specimens from patients with high-grade NECC, a large proportion of women with this disease will have at least one targetable alteration. Treatments based on these gene alterations may offer additional targeted therapies for women with recurrent disease, who currently have very limited therapeutic options. Patients with tumors that harbor RB1 alterations have decreased OS. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results